logo-loader

Rovio Entertainment, Angry Birds, Roku and Zynerba Pharmaceuticals - PRE-MARKET

Last updated: 07:34 29 Sep 2017 EDT, First published: 02:34 29 Sep 2017 EDT

Rovio Entertainment, Angry Birds, Roku and Zynerba Pharmaceuticals Inc  - PRE-MARKET
Rovio Entertainment makes Angry Birds

After the record finish, US futures show a mixed start to the day's proceedings on Wall Street.

Likely to be of big interest is Rovio Entertainment, which makes the game Angry Birds, which priced its IPO (initial public offering) and has now started trading in Helsinki and will begin changing hands on NASDAQ Helsinki's official list on October 3.

It priced shares at €11.50 (US$13.50) a share, valuing the Finnish tech firm at over US$1bn, and on debut,  shares added over 5%.

Some commentators suggested that given that the IPO was multiple times oversubscribed, the share rise at launch was not so overtly large.

 

Speaking  of floats, yesterday Roku (NASDAQ: ROKU) made its debut in New York and the streaming service got off to a flying start.

 

The video-streaming firm backed by Fox, saw shares jump up to 78% when it made its debut in New York after it raised US$219mln in an initial public offering that was priced towards the upper end of what it had expected.

The stock is likely to again be closely monitored today by traders.

Shares in Zynerba Pharmaceuticals Inc (NASDAQ:ZYNE) added 3.81% to US$9.80 in after hours deals after it reported positive top-line results for its phase 2 study of its candidate to treat children with Fragile X syndrome.

Fragile X Syndrome is a genetic condition and is the most common known cause of inherited learning disabilities.

The cannabinoid transdermal gel “successfully met its primary endpoint” on the Anxiety, Depression and Mood Scale (ADAMS) and showed “clinically meaningful improvements” in behaviour, according to a statement from the firm.

BenevolentAI advances novel ulcerative colitis treatment through Phase 1a trial

BenevolentAI (OTC:BAIVF) chief scientific officer Dr Anne Phelan joins Proactive's Stephen Gunnion with positive safety data from the Phase 1a, first-in-human, clinical study of BEN-8744 in healthy volunteers. Phelan explained that BEN-8744 is a potent, selective PD10 inhibitor, uniquely...

1 hour, 13 minutes ago